# The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer

## TL;DR

This review discusses how PSMA PET/CT imaging improves prostate cancer diagnosis, staging, and personalized treatment, especially with radioligand therapy.

## Contribution

The paper highlights PSMA PET/CT's role in personalized treatment and its potential as a prognostic tool for prostate cancer outcomes.

## Key findings

- PSMA PET/CT provides superior diagnostic accuracy for detecting prostate cancer spread.
- Variability in PSMA expression influences personalized treatment strategies, including radioligand therapy.
- PSMA PET/CT improves patient outcomes and reduces unnecessary interventions in prostate cancer management.

## Abstract

The review explores the critical role of prostate-specific membrane antigen (PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT offers superior diagnostic capabilities for identifying prostate cancer’s spread, with potential as a prognostic indicator for the disease’s recurrence and survival. It highlights PSMA’s variability in expression, impacting personalised treatment plans, notably in radioligand therapy with [177Lu] Lu-PSMA-617. This technology enhances treatment strategies, improves outcomes, and reduces unnecessary interventions, marking a significant advancement in personalised prostate cancer management.

The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA’s expression and its impact on personalised treatment, particularly the use of [177Lu] Lu-PSMA-617 radioligand therapy. This review emphasises the essential role of PSMA PET/CT in enhancing treatment approaches, improving patient outcomes, and reducing unnecessary interventions, positioning it as a key element in personalised PCa management.